The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.

Despite comedians’ assertions to the contrary, sex-associated headaches are not funny. But medications can help relieve or even prevent them. Comedians have long joked about spouses avoiding sex by ...

Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease ...

The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to ...

The FDA has granted fast track designation to Scholar Rock’s apitegromab (Isembyld), a muscle-targeting therapy recently approved for the treatment of spinal muscular atrophy (SMA), for patients ...

Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes] ...

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...

"Unmet Needs and Mechanisms Behind Newer Agitation Therapies" takes up what still remains unmet in agitation care, and the biology behind a newer treatment option.

EPOCH is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) trial being conducted at National Taiwan University Hospital. The study was registered in March 2024, and ...